NM
Nathan L. Mata
Chief Scientific Officer

Nathan L. Mata insider trades: Belite Bio (BLTE) stock sales

Chief Scientific Officer, Belite Bio Last trade May 7, 2026 13 Form 4 filings
$1.9M
Sold, last 12 months
12 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2026
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Nathan reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 7, 2026BLTE↓ Sell$102K
May 6, 2026BLTE↓ Sell$154K
May 5, 2026BLTE↓ Sell$156K
May 4, 2026BLTE↓ Sell$156K
Apr 30, 2026BLTE↓ Sell$157K
Apr 29, 2026BLTE↓ Sell$156K
Apr 28, 2026BLTE↓ Sell$159K
Apr 27, 2026BLTE↓ Sell$163K
Apr 22, 2026BLTE↓ Sell$170K
Apr 21, 2026BLTE↓ Sell$166K
Apr 20, 2026BLTE↓ Sell$164K
Apr 15, 2026BLTE↓ Sell$168K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other BLTE insiders

Open-market trades in the last 12 months

About Nathan L. Mata's insider trades

Nathan L. Mata is Chief Scientific Officer at Belite Bio (BLTE). Since Apr 15, 2026, Nathan has reported no open-market purchases and 12 sales worth $1.9M on SEC Form 4. In the last 12 months: 12 sales ($1.9M).

Their filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BLTE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.